Abstract
Glucagon-like peptide-1 receptor (GLP-1R) is an important therapeutic target for the treatment of type-2 diabetes. Currently-available GLP-1R agonists in clinic are peptides that require injection. It is necessary to develop oral small molecule drugs to provide conventional therapeutics for this chronic disease. At present, nuclear magnetic resonance, ELISA method and isotope tracing, have been used to screen small molecule drugs for anti-type 2 diabetes, but these methods have the disadvantages of either operational cumbersome or high risk.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
